These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 24375920)

  • 1. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
    Bautista F; Paci A; Minard-Colin V; Dufour C; Grill J; Lacroix L; Varlet P; Valteau-Couanet D; Geoerger B
    Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
    del Bufalo F; Carai A; Figà-Talamanca L; Pettorini B; Mallucci C; Giangaspero F; Antonelli M; Badiali M; Moi L; Bianco G; Cacchione A; Locatelli F; Ferretti E; Mastronuzzi A
    J Transl Med; 2014 Dec; 12():356. PubMed ID: 25524464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilomyxoid astrocytoma treated successfully with vemurafenib.
    Skrypek M; Foreman N; Guillaume D; Moertel C
    Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
    Sharman JP; Chmielecki J; Morosini D; Palmer GA; Ross JS; Stephens PJ; Stafl J; Miller VA; Ali SM
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e161-3. PubMed ID: 24997557
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RASopathic alopecia: hair changes associated with vemurafenib therapy.
    Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
    J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
    [No Abstract]   [Full Text] [Related]  

  • 11. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
    Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
    J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxic epidermal necrolysis induced by vemurafenib.
    Lapresta A; Dotor A; González-Herrada C
    Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
    [No Abstract]   [Full Text] [Related]  

  • 14. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib.
    Aguilera D; Janss A; Mazewski C; Castellino RC; Schniederjan M; Hayes L; Brahma B; Fogelgren L; MacDonald TJ
    Pediatr Blood Cancer; 2016 Mar; 63(3):541-3. PubMed ID: 26579623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Radiosensitization induced by vemurafenib].
    Ducassou A; David I; Delannes M; Chevreau C; Sibaud V
    Cancer Radiother; 2013; 17(4):304-7. PubMed ID: 23810304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
    Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B
    Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib Active in Iodine-Refractory Thyroid Cancer.
    Cancer Discov; 2016 Oct; 6(10):OF4. PubMed ID: 27554612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
    Ribas A; Zhang W; Chang I; Shirai K; Ernstoff MS; Daud A; Cowey CL; Daniels G; Seja E; O'Laco E; Glaspy JA; Chmielowski B; Hill T; Joe AK; Grippo JF
    J Clin Pharmacol; 2014 Apr; 54(4):368-74. PubMed ID: 24374975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma.
    Beland B; Tsang RY; Sutherland G
    J Neurooncol; 2018 May; 137(3):667-669. PubMed ID: 29335912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.